Rituximab 是一种抗 CD20 嵌合单克隆抗体，可用于某些自身免疫疾病和癌症的研究。

Purity

Anti-CD20 Reference Antibody (rituximab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC

The purity of Anti-CD20 Reference Antibody (rituximab) is 98.97%, determined by SEC-HPLC.
ELISA

Immobilized human CD20 His at 2 μg/mL can bind Anti-CD20 Reference Antibody (rituximab), EC50=0.01573/0.01258 μg/mL.
FACS

Raji cells were stained with Anti-CD20 Reference Antibody (rituximab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=1.334 μg/mL.

CDC

Anti-CD20 Reference Antibody (rituximab)-induced CDC activity was evaluated using Raji Cell. The max Lysis rate was approximately 74%.
ADCC

Anti-CD20 Reference Antibody (rituximab)-induced CDC activity was evaluated using Raji Cell. The max Lysis rate was approximately 74%.

-25~-15℃保存，有效期1年。